Company
Headquarters: Taipei City, Taiwan
TW$4.58 Billion
TWD as of Jan. 1, 2024
US$149.4 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $192.67 B |
| Stryker Corporation | $113.24 B |
| Medtronic | $111.60 B |
| Boston Scientific Corporation | $85.22 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region. The company offers its products under the Ortho-K myopia management lens, HiClear gas permeable (GP) lens, Briomoist lens care systems, SynergEyes hybrid lens, and Large Diameter GP lens. It also provides OEM/ODM collaboration services. The company is based in Taipei City, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Brighten Optix Corp has the following listings and related stock indices.
Stock: TWSE: 6747 wb_incandescent